These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

968 related items for PubMed ID: 18408564

  • 1. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.
    Fukudo M, Yano I, Yoshimura A, Masuda S, Uesugi M, Hosohata K, Katsura T, Ogura Y, Oike F, Takada Y, Uemoto S, Inui K.
    Pharmacogenet Genomics; 2008 May; 18(5):413-23. PubMed ID: 18408564
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients.
    Fukudo M, Yano I, Masuda S, Goto M, Uesugi M, Katsura T, Ogura Y, Oike F, Takada Y, Egawa H, Uemoto S, Inui K.
    Clin Pharmacol Ther; 2006 Oct; 80(4):331-45. PubMed ID: 17015051
    [Abstract] [Full Text] [Related]

  • 7. Impact of cytochrome P450 3A5 polymorphism in graft livers on the frequency of acute cellular rejection in living-donor liver transplantation.
    Uesugi M, Kikuchi M, Shinke H, Omura T, Yonezawa A, Matsubara K, Fujimoto Y, Okamoto S, Kaido T, Uemoto S, Masuda S.
    Pharmacogenet Genomics; 2014 Jul; 24(7):356-66. PubMed ID: 24911663
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients.
    Press RR, Ploeger BA, den Hartigh J, van der Straaten T, van Pelt J, Danhof M, de Fijter JW, Guchelaar HJ.
    Ther Drug Monit; 2009 Apr; 31(2):187-97. PubMed ID: 19258929
    [Abstract] [Full Text] [Related]

  • 10. Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.
    Tada H, Tsuchiya N, Satoh S, Kagaya H, Li Z, Sato K, Miura M, Suzuki T, Kato T, Habuchi T.
    Transplant Proc; 2005 May; 37(4):1730-2. PubMed ID: 15919447
    [Abstract] [Full Text] [Related]

  • 11. CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on Tacrolimus dose requirements and clinical outcome after renal transplantation.
    Glowacki F, Lionet A, Buob D, Labalette M, Allorge D, Provôt F, Hazzan M, Noël C, Broly F, Cauffiez C.
    Nephrol Dial Transplant; 2011 Sep; 26(9):3046-50. PubMed ID: 21677300
    [Abstract] [Full Text] [Related]

  • 12. CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation.
    Goto M, Masuda S, Kiuchi T, Ogura Y, Oike F, Okuda M, Tanaka K, Inui K.
    Pharmacogenetics; 2004 Jul; 14(7):471-8. PubMed ID: 15226679
    [Abstract] [Full Text] [Related]

  • 13. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation.
    Niioka T, Satoh S, Kagaya H, Numakura K, Inoue T, Saito M, Narita S, Tsuchiya N, Habuchi T, Miura M.
    Transplantation; 2012 Nov 27; 94(10):1013-9. PubMed ID: 23073468
    [Abstract] [Full Text] [Related]

  • 14. Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients.
    Wei-lin W, Jing J, Shu-sen Z, Li-hua W, Ting-bo L, Song-feng Y, Sheng Y.
    Liver Transpl; 2006 May 27; 12(5):775-80. PubMed ID: 16628701
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Influence of cytochrome P450 (CYP) 3A4*1G polymorphism on the pharmacokinetics of tacrolimus, probability of acute cellular rejection, and mRNA expression level of CYP3A5 rather than CYP3A4 in living-donor liver transplant patients.
    Uesugi M, Hosokawa M, Shinke H, Hashimoto E, Takahashi T, Kawai T, Matsubara K, Ogawa K, Fujimoto Y, Okamoto S, Kaido T, Uemoto S, Masuda S.
    Biol Pharm Bull; 2013 May 27; 36(11):1814-21. PubMed ID: 24189425
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Relation between mRNA expression level of multidrug resistance 1/ABCB1 in blood cells and required level of tacrolimus in pediatric living-donor liver transplantation.
    Goto M, Masuda S, Kiuchi T, Ogura Y, Oike F, Tanaka K, Uemoto S, Inui K.
    J Pharmacol Exp Ther; 2008 May 27; 325(2):610-6. PubMed ID: 18252812
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.